H.B. Fuller stock
FULNYSEH.B. Fuller Company, Basic MaterialsISIN US3596941068
53Score 53 out of 100, Neutral
Price and trend
45 / 100
Price history
−12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 12% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 25% below its 52-week high. Largest decline in 20 years: 69% (September 2007 to March 2009).
Chart figures for advanced users
- SMA 50$50.67
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$49.13
- The lowest closing price of the last twelve months.
- Resistance$67.49
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- H.B. Fuller Company belongs to the Chemicals (Specialty) industry (United States) and, with a market value of $2.73B, is number 79 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.47B (down 2.7% year on year) and earnings of $151.97M (up 16.7%).
- For fiscal 2026, analysts expect on average revenue of $3.61B (up 3.8%) and adjusted earnings per share of $4.85 (up 13.9%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 291 of 467 in Basic Materials, median 58.
- The P/E is 14.1 (Chemicals (Specialty) median 24.4, own median of recent years 23.2).
- Our model puts fair value at $76.52, with the price 34% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 39 years.
- Modestly valuedP/E 14.1, Chemicals (Specialty) median 24.4, own median 23.2.Valuation 85
- Below fair valuePrice 34% below the fair value of $76.52.Valuation 85
Weaknesses
- Interest barely coveredOperating profit covers interest only 2.6 times.Stability 59
Its standout strengths are valuation and fundamentals, while growth and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 55 to 53.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $58.86 and expensive above $109.31 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $65.33 (cash-flow model) and $87.71 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $71.48, at 8.5% it would be $83.71.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 29 Aug 2026, revenue rose 1.5% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating 11%, net 4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 13 Jan 2027in 62 days
- Last reported
- 23 Sep 2026EPS reported $1.52 (expected $1.47)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.850.0%
- Revenue
- $3.61B0.0%
- Earnings per share
- $5.15−1.0%
- Revenue
- $3.87B−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.3%2026 outlook updated to adjusted EBITDA of $655 million to $670 million and EPS of $4.70 to $4.85; the company gave no comparison with the old forecast.
“Adjusted EBITDA for fiscal 2026 is now expected to be in the range of $655 million to $670 million, and adjusted EPS is now expected to be in the range of $4.70 to $4.85.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 24 Sep 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
9 insiders bought on the open market between 28 Sept 2026 and 16 Oct 2026, $1.15M in total. One insider sold, $653,842 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Weaver Nathan D.Sale
11 Nov 2026, Exec VP, Business Transform.
- Shares
- 1,200
- Price
- $50.43
- Value
- $60,510
- Malik Muhammad ShahbazPurchase
16 Oct 2026, Senior VP, BAS
- Shares
- 478.66
- Price
- $52.23
- Value
- $25,000
- Bailly R JeffreyPurchase
7 Oct 2026, Board
- Shares
- 10,000
- Price
- $50.00
- Value
- $500,000
Show 9 more
- Martin Celine ChristinePurchase
30 Sept 2026, Board
- Shares
- 464.6
- Price
- $49.50
- Value
- $22,998
- Happe Michael JPurchase
29 Sept 2026, Board
- Shares
- 2,000
- Price
- $49.63
- Value
- $99,250
- Lauber Charles TPurchase
29 Sept 2026, Board
- Shares
- 2,005
- Price
- $49.87
- Value
- $99,985
- Zaheer SrilataPurchase
29 Sept 2026, Board
- Shares
- 40
- Price
- $49.97
- Value
- $1,999
- Handley Thomas WPurchase
28 Sept 2026, Board
- Shares
- 2,000
- Price
- $49.41
- Value
- $98,820
- Rasmussen Trangsrud Teresa JPurchase
28 Sept 2026, Board
- Shares
- 2,042
- Price
- $48.96
- Value
- $99,984
- Florness Daniel LPurchase
28 Sept 2026, Board
- Shares
- 2,030
- Price
- $49.34
- Value
- $100,160
- Zaheer SrilataPurchase
28 Sept 2026, Board
- Shares
- 2,000
- Price
- $49.06
- Value
- $98,120
- Weaver Nathan D.Sale
11 Aug 2026, Exec VP, Business Transform.
- Shares
- 9,561
- Price
- $62.06
- Value
- $593,332
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at H.B. Fuller
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 53
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- Azelis GroupAZE.BR $3.18B59
- HawkinsHWKN $3.16B69
- CalumetCLMT $3.15B47
- WD-40WDFC $2.94B73
- Quaker HoughtonKWR $2.68B54
- IngevityNGVT $2.14B60
- ChemoursCC $2.07B32
- Minerals TechnologiesMTX $1.93B45
ETFs that hold H.B. Fuller
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.16% | 0.30% | €2.28B |
| State Street SPDR S&P U.S. Dividend Aristocrats UCITS ETF (Dist)SPYD | 0.11% | 0.35% | €3.62B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.07% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.06% | 0.35% | €434.1M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.04% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 29 Nov 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Mar 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.